Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Could Japan's Chuikyo Embrace NICE Model As New Chairman Takes Reign?

This article was originally published in PharmAsia News

Executive Summary

The new chairman of Japan's Central Social Medical Insurance Council (Chuikyo), the committee that determines drug pricing for Japan's National Health Insurance, will consider the possibility of linking drug pricing to health technology assessments, similar to the UK's National Institute for Health and Clinical Excellence
Advertisement

Related Content

EFPIA Hopes To Shift Conversation In Japan From Pricing To Funding
Japan 2012 NHI Price Revision Takes Shape, Long-Listed Products See Smaller Cuts Than Expected
Chuikyo's Pilot For Premium Reimbursement Pricing Under Review: One Of Three Fates By Year-end
Chuikyo's Pilot For Premium Reimbursement Pricing Under Review: One Of Three Fates By Year-end
NICE Rejects Leukemia Drugs On Eve Of Conference That Likely Will Debate Cancer Policies, NICE's Future
NICE Rejects Leukemia Drugs On Eve Of Conference That Likely Will Debate Cancer Policies, NICE's Future
Japan's MHLW Approves Request For Needed Drugs That Can Bypass Clinical Trials
Japan's Improved Clinical Trial Requirements Bring Positive Impact To China, Korea Development
NICE Likely To Lose Cost-Watchdog Status By 2013
MHLW Releases New Drug Pricing Report Amid Deadlock In Price Revision Exemption Debate
Advertisement
UsernamePublicRestriction

Register

SC078149

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel